Russell K. Portenoy, MD, Chairman, Department of Pain Medicine & Palliative Care at Beth Israel Medical Center in New York, reviews government initiatives to curb the abuse of opioid medications. These include the FDA’s Risk Evaluation & Mitigation Strategies, or R.E.M.S. which will impose mandates on manufacturers, dispensers and prescribers. Dr. Portenoy emphasizes the importance of becoming familiar not only with R.E.M.S. but also with emerging state regulations.
This content was developed with Russell Portenoy, MD.
Russell Portenoy, MD has indicated the following financial disclosures during the past 12 months:
- Advisor/speaker
- Arsenal Medical Inc.
- Grupo Ferrer
- Xenon
Departmental educational/research grants
- Ameritox
- Archimedes Pharmaceuticals
- Boston Scientific
- Covidien Mallinckrodt Inc.
- Endo Pharmaceuticals
- Forest Labs
- K-Pax Pharmaceuticals
- Meda Pharmaceuticals
- Medtronics
- Otsuka Pharma
- ProStrakan
- Purdue Pharma
- Salix
- St. Jude Medical
